X4 Pharmaceuticals Inc. XFOR
$4.03
▲ +3.09% 24H
About
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics targeting rare diseases of the immune system and rare hematology diseases. Its lead product, XOLREMDI (mavorixafor), is an orally bioavailable selective antagonist of the chemokine re…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees45
TickerXFOR
Statistics
Market Cap$379.6M
Revenue (TTM)$6.5M
Net Income-$79.2M
Net Margin-1218.4%
EPS$-1.87
P/E0.71
P/S40.60
P/B2.17
EV/EBITDA-2.18
ROE-104.2%
Dividend Yield—
Price$4.03
Data: Twelve Data · Revenue = mcap / P/S